Navigation Links
Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology
Date:6/2/2011

CINCINNATI, June 2, 2011 /PRNewswire/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced the appointment of Robert Shepard, MD, FACP, as Executive Director, Oncology, Medical Affairs effective immediately.  Dr. Shepard is a leading authority on clinical development in oncology, bringing more than four decades of oncology research experience to Kendle. He will oversee the development of oncology programs for customers worldwide, providing medical, safety and scientific support to clinical research teams, investigators and customer contacts.  

"We are delighted Dr. Shepard has joined Kendle," said Melanie A. Bruno, PhD, Vice President, Regulatory and Medical Affairs. "His unsurpassed experience and expertise will be invaluable to our customers as we work with them to bring new oncology therapies to market."  

Dr. Shepard has extensive research credentials in hematology and oncology; is board certified in oncology, hematology and internal medicine; and has a wide array of experience in translational medicine and clinical research. He has been actively involved in oncology research since 1970 and has been responsible for the complete clinical development of several drugs and immune therapies for biopharmaceutical companies, including serving as the consulting Chief Medical Officer for six companies.

Dr. Shepard is a Magna cum Laude graduate of Harvard University in biochemical sciences and molecular biophysics and studied in the Harvard-M.I.T. Health Sciences program.  He earned his medical degree from Duke University in the Medical Scientist Training Program, which included two years of graduate training in immunology.  Dr. Shepard completed a fellowship in hematology and oncology at the Tufts-New England Medical Center where he conducted laboratory research in leukemias, myeloma and myelodysplasia. Dr. Shepard also completed a postdoctoral fellowship in pharmacology and molecular genetics at the Dana-Farber Cancer Center and Harvard Medical School.  He has held academic appointments at Harvard University, Tufts University and the University of Virginia.

To meet Dr. Shepard at the American Society of Clinical Oncology (ASCO) Annual Meeting June 3-7 in Chicago and learn more about Kendle's expertise in oncology clinical development programs, please email info@kendle.com or contact us at +1 800 733 1572.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing products to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

For more information, please visit www.kendle.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to Dr. Shepard's anticipated contribution to programs for Kendle customers. Words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "will," "should," "may," and other similar expressions are intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of Kendle's management and involve a number of significant risks and uncertainties, many of which are difficult to predict and are generally beyond the control of Kendle. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional factors that could cause Kendle's results to differ materially from those described in the forward-looking statements can be found in the periodic reports filed with the Securities and Exchange Commission, which are available at the Securities and Exchange Commission's website (http://www.sec.gov) at no charge. Kendle assumes no responsibility to update any forward-looking statements as a result of new information or future developments except as expressly required by law.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kendle Experts to Present at the Drug Information Association 44th Annual Meeting
2. Kendle Experts to Share Insights at the Regulatory Affairs Professionals Society Annual Conference and Exhibition
3. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
4. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
5. Kendle Receives Approval From Indian Government to Proceed With Development of Operations Center in Special Economic Zone
6. Kendle Launches New Global Biostatistics Infrastructure
7. Kendle is First Global CRO to Achieve ISO 9001:2008 Certification in China Through Beijing Affiliate
8. Kendle Executive to Share Insights at World Pharma Trials Asia 2010
9. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
10. Kendle Advances Early Stage Drug Development with ElMindAs Innovative Brain Network Activation Technology
11. Kendle to Present at 2010 Wells Fargo Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... 19, 2017  nThrive™, an independent Patient-to-Payment? solutions ... thought leadership at the 2017 HIMSS Conference. The ... award from KLAS. nThrive will host ... how market trends shape the holistic, integrated revenue ... comprehensive Patient Access solution. The panel will reveal ...
(Date:2/18/2017)... Feb. 17, 2017 Research and Markets has announced ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
(Date:2/17/2017)... PUNE, India , February 17, 2017 ... Product (Airborne Particle Counters, Liquid Particle Counters), Application (Cleanroom Monitoring, Contamination ... Global Forecast to 2021" published by MarketsandMarkets, the market is expected ... in 2016, at a CAGR of 3.7% from 2016 to 2021. ... ...
Breaking Medicine Technology:
(Date:2/19/2017)... OH (PRWEB) , ... February 19, 2017 , ... Braun ... The JEMS Conference & Exposition, the event will take place February 23-25, 2017 at ... Industries will be in Booth #909 with three new ambulances on display. ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... home healthcare, will join forces with Healthwise ® at HIMSS 2017 ... the industry leader in evidence-based health education, technology and services, will demonstrate a ...
(Date:2/18/2017)... ... ... Butler Mobility invited Ken Matthews to visit its manufacturing facility and showroom ... impressed with the safety and reliability of the Stannah Stairlift as well as with ... endorsement by Ken Matthews can be heard on News Radio WHP 580 weekdays from ...
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion Volume 2 ... ’ ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. Great ... pick and choose from hand-crafted trend-setting designs with smooth animations that will add ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... kept pace. Enovate Medical has introduced an innovative workstation designed to reduce nursing ... nurses, the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative ...
Breaking Medicine News(10 mins):